Image: Shutterstock

'Obe­si­ty plus': What’s next for GLP-1s?

No­vo Nordisk and Eli Lil­ly are set to make bil­lions of dol­lars each year off their GLP-1s, but pa­tients and pre­scribers are still ea­ger for …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.